JP2018534236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534236A5 JP2018534236A5 JP2018507018A JP2018507018A JP2018534236A5 JP 2018534236 A5 JP2018534236 A5 JP 2018534236A5 JP 2018507018 A JP2018507018 A JP 2018507018A JP 2018507018 A JP2018507018 A JP 2018507018A JP 2018534236 A5 JP2018534236 A5 JP 2018534236A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 102000013498 tau Proteins Human genes 0.000 claims description 33
- 108010026424 tau Proteins Proteins 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 7
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 6
- 206010034010 Parkinsonism Diseases 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 6
- 208000017004 dementia pugilistica Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 4
- 206010059245 Angiopathy Diseases 0.000 claims description 3
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 208000026072 Motor neurone disease Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 102000029797 Prion Human genes 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000004227 basal ganglia Anatomy 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 230000002739 subcortical effect Effects 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 210000001779 taste bud Anatomy 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000011503 in vivo imaging Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204699P | 2015-08-13 | 2015-08-13 | |
| US62/204,699 | 2015-08-13 | ||
| US201562211123P | 2015-08-28 | 2015-08-28 | |
| US62/211,123 | 2015-08-28 | ||
| PCT/US2016/046513 WO2017027685A2 (en) | 2015-08-13 | 2016-08-11 | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534236A JP2018534236A (ja) | 2018-11-22 |
| JP2018534236A5 true JP2018534236A5 (enExample) | 2019-09-19 |
| JP6913078B2 JP6913078B2 (ja) | 2021-08-04 |
Family
ID=57984099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507018A Active JP6913078B2 (ja) | 2015-08-13 | 2016-08-11 | タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10988528B2 (enExample) |
| EP (1) | EP3334453A4 (enExample) |
| JP (1) | JP6913078B2 (enExample) |
| CN (1) | CN108135986B (enExample) |
| WO (1) | WO2017027685A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019009817A (es) | 2017-02-17 | 2019-11-21 | Denali Therapeutics Inc | Anticuerpos anti-tau y metodos de uso de los mismos. |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| JP7290645B2 (ja) * | 2017-12-13 | 2023-06-13 | エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド | ＥＧＦＲｖＩＩＩ抗体ならびにその複合体、製造方法および使用 |
| WO2020123492A1 (en) | 2018-12-10 | 2020-06-18 | New York University | Monoclonal antibodies targeting c-terminal region of phosphorylated tau |
| CA3135181A1 (en) | 2019-04-05 | 2020-10-08 | B-Portal Biologics, Inc. | Fusion constructs and uses thereof |
| US11155609B2 (en) | 2019-04-05 | 2021-10-26 | TauC3 Biologies Limited | Anti-TAUC3 antibodies and uses thereof |
| CA3138550A1 (en) * | 2019-04-30 | 2020-11-05 | Target Discovery Merger Sub II, LLC | Cancer associated antibody compositions and methods of use |
| CN110679549B (zh) * | 2019-11-05 | 2021-08-20 | 南通大学 | 一种阿尔茨海默病小鼠模型的构建方法 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| AU650629B2 (en) | 1989-08-09 | 1994-06-30 | Rhomed Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| US5434050A (en) | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| EP0911390B1 (en) | 1991-12-06 | 2009-08-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein kinases as tools for the diagnosis and treatment of Alzheimer's disease |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| PT804070E (pt) | 1993-03-09 | 2000-11-30 | Genzyme Corp | Isolamento de componentes de interesse a partir do leite. |
| EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US6136548A (en) | 1994-11-22 | 2000-10-24 | Rutgers, The State University Of New Jersey | Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| NZ332566A (en) | 1996-05-22 | 2000-08-25 | Novopharm Biotech Inc | Antigen binding fragments that specifically detect cancer cells |
| WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| ATE360392T1 (de) | 2000-11-02 | 2007-05-15 | Cornell Res Foundation Inc | In vivo multiphoton diagnostische detektion und bilddarstellung einer neurodegenerativen erkrankung |
| AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| AU2002314794A1 (en) | 2001-05-23 | 2002-12-03 | New York University | Detection of alzheimer's amyloid by magnetic resonance imaging |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| CN102659946A (zh) * | 2002-03-13 | 2012-09-12 | 拜奥根Idec马萨诸塞公司 | 抗αvβ6抗体 |
| ES2367311T3 (es) | 2004-04-15 | 2011-11-02 | University Of Florida Research Foundation, Inc. | Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales. |
| MY148646A (en) * | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| EP1879613B1 (en) | 2005-05-05 | 2011-11-30 | Merck Sharp & Dohme Corp. | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| EA016609B1 (ru) | 2005-11-28 | 2012-06-29 | Генмаб А/С | Рекомбинантные моновалентные антитела и способы их получения |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008140639A2 (en) | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| WO2009033743A1 (en) * | 2007-09-13 | 2009-03-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| EP2408807B1 (en) | 2009-03-18 | 2021-07-21 | AC Immune SA | Method for therapeutic use |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| CN102596221B (zh) * | 2009-06-10 | 2019-06-04 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| KR20120049900A (ko) | 2009-07-30 | 2012-05-17 | 화이자 백신스 엘엘씨 | 항원성 타우 펩타이드 및 이의 용도 |
| BR112012028010A2 (pt) * | 2010-05-03 | 2017-09-26 | Genentech Inc | anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero |
| ES2714692T3 (es) * | 2011-01-31 | 2019-05-29 | Tau Bio Logic Corp | Tratamiento de tauopatías |
| US9751942B2 (en) * | 2012-03-29 | 2017-09-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-LAMP5 antibody and utilization thereof |
| GB201319761D0 (en) * | 2013-11-08 | 2013-12-25 | Nordic Bioscience As | Biomarkers of disease progression |
| CN107073297B (zh) | 2014-07-08 | 2021-09-14 | 纽约大学 | Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途 |
| WO2017189963A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
-
2016
- 2016-08-11 US US15/750,975 patent/US10988528B2/en active Active
- 2016-08-11 CN CN201680057687.XA patent/CN108135986B/zh active Active
- 2016-08-11 JP JP2018507018A patent/JP6913078B2/ja active Active
- 2016-08-11 WO PCT/US2016/046513 patent/WO2017027685A2/en not_active Ceased
- 2016-08-11 EP EP16835896.8A patent/EP3334453A4/en active Pending
-
2021
- 2021-02-16 US US17/176,374 patent/US11958898B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534236A5 (enExample) | ||
| JP2018535921A5 (enExample) | ||
| Vaikath et al. | Antibodies against alpha‐synuclein: tools and therapies | |
| JP2017532288A5 (enExample) | ||
| JP2012530055A5 (enExample) | ||
| JP6263473B2 (ja) | 脳における高レベルのα−シヌクレインを診断するための抗α−シヌクレイン抗体の使用 | |
| JP2015505665A5 (enExample) | ||
| US20160077112A1 (en) | Detection of Misfolded Proteins | |
| JP2016105097A5 (enExample) | ||
| JP2014502141A5 (enExample) | ||
| US20160077110A1 (en) | Detection of Misfolded Amyloid Beta Protein | |
| FI3334761T3 (fi) | Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa | |
| IL310464A (en) | Anti-phf-tau antibodies and uses thereof | |
| DK2764367T3 (en) | PROCEDURE FOR DIAGNOSTIZING ALZHEIMER'S DISEASE (AD) | |
| RU2016144178A (ru) | Антитело против muc1 или его антигенсвязывающий фрагмент и его применение | |
| JP2016519932A5 (enExample) | ||
| JP2014527398A5 (enExample) | ||
| JP2014506244A5 (enExample) | ||
| KR20230037647A (ko) | 타우병증 또는 아밀로이드성 질환을 검출하기 위한 혈액-기반 검정 | |
| WO2017027685A3 (en) | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy | |
| JP2014507649A (ja) | ヒト血液中の抗βアミロイド抗体の測定 | |
| JP7215903B2 (ja) | タンパク質の構造型の検出 | |
| Yoshihara et al. | Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro | |
| JP7210612B2 (ja) | 抗ａベータ抗体及びその使用 | |
| WO2023245063A2 (en) | Identification of tdp-43 cryptic exon-encoded neoepitopes as functional fluid biomarkers for alzheimer's disease and related dementia |